Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i> mutant acute myeloid leukemia-Reference-Cited by-同舟云学术

Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3- mutant acute myeloid leukemia

Published:2024-04-22 Issue:8 Volume:65 Page:1136-1144
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bewersdorf Jan Philipp¹^ORCID,Patel Kishan K.²,Shallis Rory M.³⁴^ORCID,Podoltsev Nikolai A.³⁴,Kewan Tariq³,Stempel Jessica³,Mendez Lourdes³,Stahl Maximilian⁵,Stein Eytan M.¹,Huntington Scott F.³⁴,Goshua George³⁶^ORCID,Zeidan Amer M.³⁵

Affiliation:

1. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

2. Department of Medicine, Brigham and Women’s Hospital, Boston, MA

3. Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT

4. Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT

5. Department of Medical Oncology, Adult Leukemia Program, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

6. Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT

Funder

American Society of Hematology Physician-Scientist Career Development Award

Leukemia and Lymphoma Society Scholar in Clinical Research

National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2344052

Reference39 articles.

1. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

2. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

3. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

4. The clinical impact of the molecular landscape of acute myeloid leukemia

5. A review of FLT3 inhibitors in acute myeloid leukemia